Pen needles are an easy and simple way to administer medication, but they have also been associated with pain, hyperglycemia, and infections from needlesticks. Because the dose cannot be adjusted, some people using insulin pens have hyperglycemia. Insulin pens have been replaced with insulin pumps in the management of diabetes in Europe as a result of their ability to carry out automated insulin suspension and lower the risk of hypoglycemia. The growth of the Pen Needles Market is seriously hampered by this.
Although there are certain therapeutic applications for needle-free pharmaceutical delivery technologies, this issue has only been partially solved. The global Pen Needles Market is anticipated to grow, but it will be constrained by a lack of medical specialists for treating hormonal imbalances and conditions like thyroid disorders, diabetes, and others, as well as a lack of patient and carer education and training regarding the proper use of pen needles.
Major Companies are Novo Nordisk A/S, Becton, Dickinson and Company, Ypsomed AG, UltiMed, Inc., TERUMO CORPORATION, HTL-STREFA, Owen Mumford Ltd., B. Braun Melsungen AG, Allison Medical, Inc., Hindustan Syringes and Medical Devices Ltd., and Artsana S.p.a.
